Hutchmed has withdrawn its EU marketing authorization application (MAA) for surufatinib, the company’s oral angio-immuno kinase inhibitor, which is approved as Sulanda in China for treating advanced neuroendocrine tumors but which the US regulator rejected in April this year.
The EU MAA was pulled after interactions between Hutchmed and reviewers at the European Medicines Agency suggested there was a low probability of a positive opinion on the MAA, the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?